"Azetidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D001384
|
| MeSH Number(s) |
D03.383.082.301
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azetidines".
Below are MeSH descriptors whose meaning is more specific than "Azetidines".
This graph shows the total number of publications written about "Azetidines" by people in this website by year, and whether "Azetidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azetidines" by people in Profiles.
-
McSweeney SM, Rayinda T, McGrath JA, Tziotzios C. Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper. Br J Dermatol. 2023 02 10; 188(2):195-197.
-
Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2011 Mar 15; 107(6):886-90.
-
Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis. 2010 Aug; 13(3):e29-31.
-
van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS. 2008 Jun; 22(6):483-8.
-
Nagarakanti R, Sodhi S, Lee R, Ezekowitz M. Chronic antithrombotic therapy in post-myocardial infarction patients. Cardiol Clin. 2008 May; 26(2):277-88, vii.
-
Ford GA, Choy AM, Deedwania P, Karalis DG, Lindholm CJ, Pluta W, Frison L, Olsson SB. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. Stroke. 2007 Nov; 38(11):2965-71.
-
Kulak JM, Fan H, Schneider JS. Beta2* and beta4* nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiol Dis. 2007 Sep; 27(3):312-9.
-
Lotke PA, Callaghan JJ, Dorr LD, Engh GH, Hanssen AD, Healy WL, Lachiewicz PF, Lonner JH, Nelson C, Ranawat CS, Ritter MA, Salvati EA, Sculco TP, Thornhill TS. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2006 May; 88(5):1163; author reply 1163-5.
-
Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med. 2006 Apr 24; 166(8):853-9.
-
Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006 Mar; 46(3):321-7.